Company Encyclopedia
View More
name
Cyclopharm Limited
CYC.AU
News
View More

Cyclopharm (ASX:CYC investor three-year losses grow to 43% as the stock sheds AU$19m this past week

Cyclopharm Limited (ASX:CYC) has seen its share price decline by 44% over the past three years, significantly underperforming the market's 42% return. Recently, the stock dropped 21% in three months and 41% over the past year. Despite a revenue growth of 4.8% annually, the company continues to report losses, raising concerns among investors. The market is focused on revenue growth, but without profits, the outlook remains uncertain. Investors are advised to consider the company's fundamentals before making decisions, as there are warning signs to be aware of.

Simplywall·
Simplywall·

Cyclopharm Limited Revises AGM Date and Director Nomination Deadline

Cyclopharm Limited has revised the date for its Annual General Meeting to May 30, 2025, with director elections on the agenda. The new deadline for director nominations is April 9, 2025. This announcement, approved by CEO James McBrayer, is crucial for stakeholders as it outlines the company's governance timeline. Cyclopharm, an ASX-listed radiopharmaceutical company, focuses on improving patient care through its product, Technegas®, used for lung imaging. The company has a market cap of A$131.1M and a year-to-date price performance of -29.43%.

Tip Ranks·
Tip Ranks·

Cyclopharm Limited Releases 2024 Corporate Governance Statement

Cyclopharm Limited has released its corporate governance statement for the financial year ending December 31, 2024, emphasizing adherence to ASX Corporate Governance Council’s principles. This announcement reflects the company's commitment to transparency and accountability, potentially enhancing its market position and stakeholder confidence. Cyclopharm operates in the healthcare sector, focusing on medical technology and services, with a current market cap of A$133.4M and a year-to-date price performance of -24.05%.

Tip Ranks·
Tip Ranks·

Cyclopharm Limited Announces AGM Date and Director Nomination Deadline

Cyclopharm Limited has announced its Annual General Meeting (AGM) will take place on May 13, 2025, with director nominations closing on March 24, 2025. This update is part of the company's governance and operational strategies. Cyclopharm, an ASX-listed radiopharmaceutical company, focuses on enhancing patient care through its product Technegas®, used for lung ventilation imaging. The company currently has a market cap of A$155.6M and has seen a year-to-date price performance of -11.67%.

Tip Ranks·
Tip Ranks·

Australian Ethical Investment Adjusts Stake in Cyclopharm

Australian Ethical Investment Ltd has announced a reduction in its stake in Cyclopharm Limited, decreasing its voting power from 10.04% to 8.88% as of January 23, 2025. This change reflects a shift in their investment strategy, potentially affecting their influence over Cyclopharm's decisions. Australian Ethical Investment focuses on ethical investment solutions, catering to clients who prioritize sustainability in their investment choices. The company's current market cap is €344.2M, with a year-to-date price performance of -3.85%.

Tip Ranks·
Tip Ranks·